Pneumagen raises £8m to accelerate Phase 2 clinical dev

Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections

Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infectionsNeumifil is being developed for the prevention and treatment of virus induced exacerbations in patients with respiratory diseaseAdvancing Neumifil into a Phase 2b...

Related Keywords

United Kingdom , Thairm Bio , Douglas Thomson , Thairm Bio Mark Bamforth , , Chronic Obstructive Pulmonary Disease , Scottish Enterprise , Esperante Ventures , Chief Executive Officer , Mark Bamforth , Dean Slagel , Managing Director ,

© 2025 Vimarsana